{
    "url": "https://en.wikipedia.org/wiki/Bentracimab",
    "title": "Bentracimab",
    "summary": "Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta among others). It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor. It is not commercially available.",
    "content": "Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta among others). It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor. It is not commercially available.\n\n\n== See also ==\nOther reversal agents for antithrombotic drugs\nAndexanet alfa\nCiraparantag\nVitamin K\nIdarucizumab\n\n\n== References ==",
    "links": [
        "Abciximab",
        "Active metabolite",
        "Aducanumab",
        "Alacizumab pegol",
        "Alirocumab",
        "Anatomical Therapeutic Chemical Classification System",
        "Andexanet alfa",
        "Angiogenesis inhibitor",
        "Antigen",
        "Antiplatelet drug",
        "Antithrombotic",
        "Ascrinvacumab",
        "Bapineuzumab",
        "Bentracimab (data page)",
        "Bevacizumab",
        "Bimagrumab",
        "Blood",
        "Blosozumab",
        "Bococizumab",
        "Bone",
        "Brolucizumab",
        "Burosumab",
        "CAS Registry Number",
        "Caplacizumab",
        "Chemical formula",
        "Ciraparantag",
        "Circulatory system",
        "ClinicalTrials.gov",
        "Clinical trial",
        "Clinical trials",
        "Crenezumab",
        "Demcizumab",
        "Denosumab",
        "Doi (identifier)",
        "Domagrozumab",
        "DrugBank",
        "Enoticumab",
        "Eptinezumab",
        "Erenumab",
        "Etaracizumab",
        "Evinacumab",
        "Evolocumab",
        "Fab fragment",
        "Faricimab",
        "Fasinumab",
        "Fremanezumab",
        "Fulranumab",
        "Fusion protein",
        "Galcanezumab",
        "Gantenerumab",
        "Growth factor",
        "Haematopoiesis",
        "Human",
        "Human musculoskeletal system",
        "Humanized antibody",
        "Icrucumab",
        "Idarucizumab",
        "Inclacumab",
        "Indium (111In) biciromab",
        "Indium (111In) imciromab",
        "Intravenous infusion",
        "KEGG",
        "Landogrozumab",
        "List of withdrawn drugs",
        "Molar mass",
        "Monoclonal antibody",
        "Monoclonal antibody therapy",
        "National Health Service",
        "Nesvacumab",
        "Neurology",
        "Opicinumab",
        "Orticumab",
        "Ozanezumab",
        "P2Y12",
        "PMID (identifier)",
        "Pharmaceutical drug",
        "Phases of clinical research",
        "Ponezumab",
        "PubChem",
        "Ralpancizumab",
        "Ramucirumab",
        "Ranibizumab",
        "Refanezumab",
        "Regulation of therapeutic goods",
        "Rinucumab",
        "Romosozumab",
        "Route of administration",
        "Solanezumab",
        "Stamulumab",
        "Tadocizumab",
        "Tanezumab",
        "Ticagrelor",
        "Trevogrumab",
        "Unique Ingredient Identifier",
        "Vanucizumab",
        "Vitamin K",
        "Volociximab",
        "WHO Model List of Essential Medicines"
    ]
}